#PsoriaticArthritis #GLP1 #Dermatology #Rheumatology #MedicalResearch To view or add a comment, sign in More Relevant Posts Clinical Insights Series 28 Focus: Cutaneous Mycoses in Immunomodulated Patients - Overview Cutaneous mycoses in immunomodulated patients, including both therapy-related and disease-associated states, present with altered patterns that often diverge from classical descriptions, leading to delayed recognition or misclassification
Patients transporting Wegovy without proper insulation, coolers, or temperature monitoring risk exposing the medication to heat, which is semaglutide's greatest enemy
Reconstitute in sterile water or sterile bacteriostatic water at neutral pH
The injection sites commonly used include the abdomen, thighs, or upper arms
OZEMPIC (semaglutide) injection, for subcutaneous use
US Food and Drug Administration (FDA) Approvals of GLP-1 and GLP1 /GIP RAs 11,22-34 However, these labels are being expanded to include additional indications for patients with a spectrum of other cardiometabolic conditions, such as obesity, cardiovascular disease, chronic kidney disease, and obstructive sleep apnea
)
